Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0058 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Ocugen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 0.3949 |
| Open* | 0.3922 |
| 1-Year Change* | -73.5% |
| Day's Range* | 0.3849 - 0.4025 |
| 52 wk Range | 0.35-1.62 |
| Average Volume (10 days) | 1.21M |
| Average Volume (3 months) | 36.09M |
| Market Cap | 99.27M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 256.50M |
| Revenue | N/A |
| EPS | -0.32 |
| Dividend (Yield %) | N/A |
| Beta | 3.97 |
| Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | 0.3913 | -0.0006 | -0.15% | 0.3919 | 0.4044 | 0.3835 |
| Nov 24, 2023 | 0.3949 | 0.0140 | 3.68% | 0.3809 | 0.3969 | 0.3799 |
| Nov 22, 2023 | 0.3799 | -0.0011 | -0.29% | 0.3810 | 0.3849 | 0.3719 |
| Nov 21, 2023 | 0.3829 | -0.0098 | -2.50% | 0.3927 | 0.3995 | 0.3806 |
| Nov 20, 2023 | 0.4046 | 0.0247 | 6.50% | 0.3799 | 0.4085 | 0.3779 |
| Nov 17, 2023 | 0.3860 | 0.0028 | 0.73% | 0.3832 | 0.3883 | 0.3659 |
| Nov 16, 2023 | 0.3608 | -0.0141 | -3.76% | 0.3749 | 0.3769 | 0.3608 |
| Nov 15, 2023 | 0.3775 | 0.0076 | 2.05% | 0.3699 | 0.3878 | 0.3699 |
| Nov 14, 2023 | 0.3699 | 0.0100 | 2.78% | 0.3599 | 0.3729 | 0.3524 |
| Nov 13, 2023 | 0.3573 | -0.0027 | -0.75% | 0.3600 | 0.3609 | 0.3508 |
| Nov 10, 2023 | 0.3599 | 0.0000 | 0.00% | 0.3599 | 0.3699 | 0.3513 |
| Nov 9, 2023 | 0.3579 | -0.0220 | -5.79% | 0.3799 | 0.3831 | 0.3549 |
| Nov 8, 2023 | 0.3829 | 0.0080 | 2.13% | 0.3749 | 0.3846 | 0.3736 |
| Nov 7, 2023 | 0.3754 | -0.0025 | -0.66% | 0.3779 | 0.3829 | 0.3701 |
| Nov 6, 2023 | 0.3779 | -0.0138 | -3.52% | 0.3917 | 0.3988 | 0.3752 |
| Nov 3, 2023 | 0.3899 | 0.0170 | 4.56% | 0.3729 | 0.3947 | 0.3699 |
| Nov 2, 2023 | 0.3708 | 0.0112 | 3.11% | 0.3596 | 0.3778 | 0.3559 |
| Nov 1, 2023 | 0.3580 | -0.0077 | -2.11% | 0.3657 | 0.3666 | 0.3499 |
| Oct 31, 2023 | 0.3624 | 0.0025 | 0.69% | 0.3599 | 0.3748 | 0.3509 |
| Oct 30, 2023 | 0.3600 | 0.0101 | 2.89% | 0.3499 | 0.3664 | 0.3454 |
Ocugen, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, February 26, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Ocugen Inc Earnings Release Q4 2023 Ocugen Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0.04262 | 0 | 0 |
| Revenue | 0 | 0.04262 | 0 | ||
| Total Operating Expense | 84.868 | 57.628 | 21.3273 | 14.5038 | 28.568 |
| Selling/General/Admin. Expenses, Total | 35.111 | 22.92 | 7.97405 | 6.0771 | 10.204 |
| Research & Development | 49.757 | 35.108 | 13.3533 | 8.08552 | 15.634 |
| Unusual Expense (Income) | -0.4 | 0 | 0.34114 | 2.73 | |
| Operating Income | -84.868 | -57.628 | -21.2847 | -14.5038 | -28.568 |
| Interest Income (Expense), Net Non-Operating | -0.079 | -0.71989 | -4.95401 | 20.031 | |
| Other, Net | 3.517 | -0.71 | 0.18266 | -0.78487 | -0.106 |
| Net Income Before Taxes | -81.351 | -58.417 | -21.822 | -20.2426 | -8.643 |
| Net Income After Taxes | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Net Income Before Extra. Items | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Net Income | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Total Adjustments to Net Income | 0 | -12.5463 | 0.121 | ||
| Income Available to Common Excl. Extra. Items | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Income Available to Common Incl. Extra. Items | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Diluted Net Income | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Diluted Weighted Average Shares | 214.6 | 195.013 | 112.236 | 13.8938 | 0.60676 |
| Diluted EPS Excluding Extraordinary Items | -0.37908 | -0.29929 | -0.30621 | -1.45695 | -14.045 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.37908 | -0.30062 | -0.30621 | -1.4324 | -9.54575 |
| Total Extraordinary Items | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 23.733 | 17.751 | 24.15 | 23.119 | 19.565 |
| Selling/General/Admin. Expenses, Total | 9.564 | 8.193 | 6.937 | 7.497 | 10.558 |
| Research & Development | 14.169 | 9.558 | 17.213 | 15.622 | 9.007 |
| Operating Income | -23.733 | -17.751 | -24.15 | -23.119 | -19.565 |
| Interest Income (Expense), Net Non-Operating | |||||
| Net Income Before Taxes | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income After Taxes | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income Before Extra. Items | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Income Available to Common Excl. Extra. Items | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Income Available to Common Incl. Extra. Items | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Diluted Net Income | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Diluted Weighted Average Shares | 238.311 | 225.524 | 220.133 | 216.591 | 215.863 |
| Diluted EPS Excluding Extraordinary Items | -0.0962 | -0.07316 | -0.09966 | -0.10121 | -0.0902 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.0962 | -0.07316 | -0.09966 | -0.10121 | -0.0902 |
| Revenue | |||||
| Other, Net | 0.808 | 1.253 | 2.211 | 1.197 | 0.094 |
| Total Adjustments to Net Income | -0.001 | ||||
| Unusual Expense (Income) |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 98.492 | 102.646 | 25.8777 | 15.7662 | 16.4 |
| Cash and Short Term Investments | 90.934 | 94.958 | 24.0393 | 7.44405 | 15.542 |
| Cash & Equivalents | 77.563 | 94.958 | 24.0393 | 7.44405 | 15.542 |
| Prepaid Expenses | 7.558 | 2.7 | 1.83836 | 1.32217 | 0.686 |
| Total Assets | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
| Property/Plant/Equipment, Total - Net | 9.963 | 2.751 | 1.06662 | 0.22246 | 0.141 |
| Intangibles, Net | |||||
| Other Long Term Assets, Total | 0.177 | 0.364 | 0.43205 | 0.81876 | 0.887 |
| Total Current Liabilities | 18.46 | 7 | 3.61355 | 4.54396 | 2.873 |
| Accounts Payable | 8.062 | 2.312 | 0.39503 | 1.89561 | 1.59 |
| Accrued Expenses | 10.398 | 4.688 | 2.97464 | 2.44236 | 1 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.23412 | 0 | 0 | |
| Other Current Liabilities, Total | 0.00976 | 0.20599 | 0.283 | ||
| Total Liabilities | 24.58 | 9.943 | 5.82591 | 5.78904 | 17.886 |
| Total Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | 0 |
| Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | |
| Other Liabilities, Total | 3.831 | 1.231 | 0.38932 | 0.17295 | 15.013 |
| Total Equity | 84.052 | 95.818 | 21.5504 | 11.0184 | -0.458 |
| Common Stock | 2.217 | 1.995 | 1.84133 | 0.52747 | 0.513 |
| Additional Paid-In Capital | 294.874 | 225.537 | 93.0587 | 62.0186 | 215.859 |
| Retained Earnings (Accumulated Deficit) | -213.018 | -131.667 | -73.3018 | -51.4798 | -216.83 |
| Total Liabilities & Shareholders’ Equity | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
| Total Common Shares Outstanding | 221.6 | 199.381 | 184.012 | 52.6252 | 1.03376 |
| Short Term Investments | 13.371 | 0 | |||
| Redeemable Preferred Stock | 0.001 | 0.001 | 0 | 0 | |
| Other Equity, Total | 0.026 | 0 | |||
| Other Current Assets, Total | 4.988 | 0 | 7 | 0.172 | |
| Property/Plant/Equipment, Total - Gross | 10.584 | 3.125 | 1.29231 | 10.427 | |
| Accumulated Depreciation, Total | -0.621 | -0.374 | -0.2257 | -10.286 | |
| Treasury Stock - Common | -0.048 | -0.048 | -0.04786 | -0.04786 | |
| Total Preferred Shares Outstanding | 0.05475 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 56.558 | 73.452 | 84.401 | 98.492 | 107.497 |
| Cash and Short Term Investments | 53.477 | 70.578 | 76.721 | 90.934 | 101.602 |
| Cash & Equivalents | 53.477 | 70.578 | 68.259 | 77.563 | 101.602 |
| Prepaid Expenses | 3.081 | 2.874 | 7.68 | 7.558 | 5.895 |
| Other Current Assets, Total | |||||
| Total Assets | 74.687 | 88.976 | 96.299 | 108.632 | 116.239 |
| Property/Plant/Equipment, Total - Net | 14.469 | 11.72 | 7.952 | 9.963 | 8.557 |
| Property/Plant/Equipment, Total - Gross | 15.528 | 12.613 | 8.739 | 10.584 | 9.135 |
| Accumulated Depreciation, Total | -1.059 | -0.893 | -0.787 | -0.621 | -0.578 |
| Other Long Term Assets, Total | 3.66 | 3.804 | 3.946 | 0.177 | 0.185 |
| Total Current Liabilities | 11.136 | 13.46 | 15.683 | 18.46 | 14.907 |
| Accounts Payable | 2.921 | 3.881 | 8.092 | 8.062 | 6.46 |
| Accrued Expenses | 6.939 | 8.313 | 6.335 | 10.398 | 8.447 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.276 | 1.266 | 1.256 | ||
| Total Liabilities | 16.292 | 18.695 | 20.499 | 24.58 | 20.936 |
| Total Long Term Debt | 1.495 | 1.472 | 1.058 | 2.289 | 2.265 |
| Long Term Debt | 1.495 | 1.472 | 1.058 | 2.289 | 2.265 |
| Other Liabilities, Total | 3.661 | 3.763 | 3.758 | 3.831 | 3.764 |
| Total Equity | 58.395 | 70.281 | 75.8 | 84.052 | 95.303 |
| Common Stock | 2.566 | 2.566 | 2.265 | 2.217 | 2.168 |
| Additional Paid-In Capital | 322.452 | 320.181 | 303.073 | 294.874 | 284.231 |
| Retained Earnings (Accumulated Deficit) | -266.603 | -252.441 | -229.516 | -213.018 | -191.079 |
| Treasury Stock - Common | -0.048 | -0.048 | -0.048 | -0.048 | -0.048 |
| Other Equity, Total | 0.027 | 0.022 | 0.025 | 0.026 | 0.03 |
| Total Liabilities & Shareholders’ Equity | 74.687 | 88.976 | 96.299 | 108.632 | 116.239 |
| Total Common Shares Outstanding | 256.5 | 256.487 | 226.427 | 221.6 | 216.688 |
| Redeemable Preferred Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Short Term Investments | 0 | 0 | 8.462 | 13.371 | |
| Total Preferred Shares Outstanding | 0.05475 | 0.05475 | 0.05475 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Cash From Operating Activities | -60.079 | -47.941 | -14.7087 | -16.8933 | -15.777 |
| Cash From Operating Activities | 0.48 | 0.229 | 0.10211 | 0.06061 | 0.45 |
| Non-Cash Items | 11.597 | 7.757 | 8.2213 | 6.40129 | -14.779 |
| Cash Taxes Paid | 0 | 0.052 | 0.105 | ||
| Cash Interest Paid | 0.001 | ||||
| Changes in Working Capital | 9.195 | 2.438 | -1.21018 | -3.11255 | 7.195 |
| Cash From Investing Activities | -16.967 | -1.816 | -0.30683 | -2.35672 | -1.113 |
| Capital Expenditures | -4.457 | -1.066 | -0.30683 | -0.02945 | -2.013 |
| Cash From Financing Activities | 59.475 | 120.676 | 31.611 | 25.0665 | 25.351 |
| Financing Cash Flow Items | -0.592 | -8.525 | -1.48355 | -0.17293 | -0.178 |
| Issuance (Retirement) of Stock, Net | 59.567 | 129.211 | 37.822 | 23.7294 | 25.529 |
| Net Change in Cash | -17.546 | 70.919 | 16.5955 | 5.81646 | 8.461 |
| Other Investing Cash Flow Items, Total | -12.51 | -0.75 | 0 | -2.32727 | 0.9 |
| Issuance (Retirement) of Debt, Net | 0.5 | -0.01 | -4.72744 | 1.51 | |
| Foreign Exchange Effects | 0.025 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.498 | -81.351 | -59.412 | -37.49 | -18.019 |
| Cash From Operating Activities | -18.24 | -60.079 | -43.165 | -28.863 | -15.066 |
| Cash From Operating Activities | 0.174 | 0.48 | 0.307 | 0.166 | 0.076 |
| Non-Cash Items | 3.053 | 11.597 | 7.721 | 5.75 | 3.497 |
| Changes in Working Capital | -4.969 | 9.195 | 8.219 | 2.711 | -0.62 |
| Cash From Investing Activities | 3.441 | -16.967 | -1.672 | -1.589 | -0.223 |
| Capital Expenditures | -1.612 | -4.457 | -2.433 | -1.589 | -0.223 |
| Cash From Financing Activities | 5.496 | 59.475 | 51.3 | 50.338 | 50.102 |
| Financing Cash Flow Items | -0.235 | -0.592 | -0.398 | -0.248 | -0.075 |
| Issuance (Retirement) of Stock, Net | 5.731 | 59.567 | 51.198 | 50.586 | 50.177 |
| Issuance (Retirement) of Debt, Net | 0.5 | 0.5 | 0 | 0 | |
| Net Change in Cash | -9.304 | -17.546 | 6.493 | 19.896 | 34.813 |
| Other Investing Cash Flow Items, Total | 5.053 | -12.51 | 0.761 | 0 | |
| Cash Taxes Paid | 0 | 0 | |||
| Foreign Exchange Effects | -0.001 | 0.025 | 0.03 | 0.01 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.6031 | 11806345 | -1208505 | 2023-06-30 | LOW |
| Luminus Management, L.L.C. | Hedge Fund | 1.5904 | 4079238 | 4079238 | 2023-06-30 | MED |
| GMT Capital Corp. | Hedge Fund | 1.5292 | 3922198 | 3922198 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5146 | 3884853 | -10098331 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.1761 | 3016537 | 1748855 | 2023-06-30 | HIGH |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1354 | 2912274 | -62660 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.1162 | 2862968 | -1798365 | 2023-06-30 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 0.9747 | 2500000 | 2500000 | 2023-06-30 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.9635 | 2471156 | 189608 | 2023-06-30 | HIGH |
| KVM Holdings, L.L.C. | Corporation | 0.4465 | 1145299 | 0 | 2023-04-13 | |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4421 | 1134020 | -384808 | 2023-06-30 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.4259 | 1092269 | 1092269 | 2023-06-30 | MED |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.4215 | 1081149 | 1081149 | 2023-06-30 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 0.4082 | 1047001 | -1373928 | 2023-06-30 | MED |
| Zhang (Junge) | Individual Investor | 0.3762 | 964904 | 0 | 2023-04-13 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3437 | 881626 | -5189880 | 2023-06-30 | LOW |
| Kompella (Uday B.) | Individual Investor | 0.2749 | 705090 | 0 | 2023-04-13 | |
| Citadel Advisors LLC | Hedge Fund | 0.2235 | 573323 | 279457 | 2023-06-30 | LOW |
| Musunuri (Shankar Ph.D) | Individual Investor | 0.1886 | 483636 | -1359897 | 2023-04-13 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.1819 | 466625 | 33988 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
Income Statement
- Annual
- Quarterly
News
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023
Crude prices extend tumble as demand fears loom ahead of next OPEC+ meeting
Crude has extended its sell-off as demand risks loom ahead of OPEC+’s meeting on November 26. We look at the drivers of oil prices and the key technical levels of WTI Crude.
13:07, 17 November 2023
AUD/USD Retests Key Resistance Zone
The US dollar weakened notably following the latest CPI data, showing a larger-than-expected dip to 3.2% in October. This decline, the first in four months, sparked a surge in AUD/USD on Tuesday, pushing prices back into a crucial resistance zone established since August (see daily candle chart below).
10:24, 17 November 2023
Strategy Smarts Part 2: Trading Trend Days
Welcome to our four-part Strategy Smarts series designed to give you some practical trading templates which build on the concepts outlined in our Day Traders Toolbox and Power Patterns series. Today’s piece centres around Trend Days; what they are, how to spot them early and most importantly, how to trade them consistently.
10:18, 15 November 2023
Apple Regain Bullish Momentum
Apple's share price has rallied since the release of their recent financial results on 2nd November, despite certain concerns over growth in China.
10:17, 14 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com